JP2013503184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503184A5 JP2013503184A5 JP2012527002A JP2012527002A JP2013503184A5 JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5 JP 2012527002 A JP2012527002 A JP 2012527002A JP 2012527002 A JP2012527002 A JP 2012527002A JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- antibody
- antigen
- mip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23842409P | 2009-08-31 | 2009-08-31 | |
| US61/238,424 | 2009-08-31 | ||
| US12/644,146 US7981398B2 (en) | 2005-04-06 | 2009-12-22 | PEGylation by the dock and lock (DNL) technique |
| US12/644,146 | 2009-12-22 | ||
| US12/731,781 US8003111B2 (en) | 2005-04-06 | 2010-03-25 | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US12/731,781 | 2010-03-25 | ||
| US12/752,649 | 2010-04-01 | ||
| US12/752,649 US8034352B2 (en) | 2005-04-06 | 2010-04-01 | Tetrameric cytokines with improved biological activity |
| US12/754,140 US8722047B2 (en) | 2005-03-03 | 2010-04-05 | Humanized anti-HLA-DR antibodies |
| US12/754,140 | 2010-04-05 | ||
| US12/754,740 US8562988B2 (en) | 2005-10-19 | 2010-04-06 | Strategies for improved cancer vaccines |
| US12/754,740 | 2010-04-06 | ||
| PCT/US2010/046889 WO2011025904A1 (en) | 2009-08-31 | 2010-08-27 | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015080993A Division JP5999217B2 (ja) | 2009-08-31 | 2015-04-10 | 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503184A JP2013503184A (ja) | 2013-01-31 |
| JP2013503184A5 true JP2013503184A5 (cg-RX-API-DMAC10.html) | 2013-09-19 |
| JP5740772B2 JP5740772B2 (ja) | 2015-07-01 |
Family
ID=43628394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527002A Active JP5740772B2 (ja) | 2009-08-31 | 2010-08-27 | 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 |
| JP2015080993A Expired - Fee Related JP5999217B2 (ja) | 2009-08-31 | 2015-04-10 | 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015080993A Expired - Fee Related JP5999217B2 (ja) | 2009-08-31 | 2015-04-10 | 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2473186A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5740772B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102481348A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2010286642B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2772572A1 (cg-RX-API-DMAC10.html) |
| IN (1) | IN2012DN01331A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011025904A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| EP2473187A4 (en) * | 2009-08-31 | 2015-09-16 | Immunomedics Inc | COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY |
| EP2552483A4 (en) * | 2010-04-01 | 2013-09-25 | Immunomedics Inc | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS |
| JP6205621B2 (ja) * | 2012-01-26 | 2017-10-04 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | 抗体を有するインターフェロンλでの標的化は抗腫瘍および抗ウイルス活性を大きく増強する |
| WO2014006225A1 (en) * | 2012-07-06 | 2014-01-09 | Innovative Technologies In Biological Systems S.L. | Fluorescent fusion polypeptide, biosensor comprising said polypeptide and uses thereof |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN105073128A (zh) * | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) * | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| ES2984656T3 (es) * | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| LT3394089T (lt) * | 2015-12-23 | 2021-11-25 | eleva GmbH | Polipeptidai, skirti komplemento aktyvacijos inhibicijai |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| CN109195620B (zh) | 2016-04-07 | 2022-06-28 | 约翰霍普金斯大学 | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| AU2019285048B2 (en) * | 2018-06-13 | 2023-06-08 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
| CA3163358A1 (en) * | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
| CA2484676A1 (en) * | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| CA2497254A1 (en) * | 2002-09-06 | 2004-03-18 | Forschungsverbund Berlin E. V. | Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
| CN101171034B (zh) * | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| CA2607056C (en) * | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| CN105709237A (zh) * | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
-
2010
- 2010-08-27 CA CA2772572A patent/CA2772572A1/en not_active Abandoned
- 2010-08-27 JP JP2012527002A patent/JP5740772B2/ja active Active
- 2010-08-27 AU AU2010286642A patent/AU2010286642B2/en active Active
- 2010-08-27 IN IN1331DEN2012 patent/IN2012DN01331A/en unknown
- 2010-08-27 EP EP10812633.5A patent/EP2473186A4/en not_active Withdrawn
- 2010-08-27 WO PCT/US2010/046889 patent/WO2011025904A1/en not_active Ceased
- 2010-08-27 CN CN2010800385485A patent/CN102481348A/zh active Pending
-
2015
- 2015-04-10 JP JP2015080993A patent/JP5999217B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513098A5 (cg-RX-API-DMAC10.html) | ||
| US10385139B2 (en) | Murine, chimeric, humanized or human anti-TNF-alpha antibodies | |
| US8282934B2 (en) | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology | |
| EP2271364B1 (en) | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology | |
| FI3903829T3 (fi) | Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja | |
| US9498542B2 (en) | Tetrameric cytokines with improved biological activity | |
| AU2013302696B2 (en) | T-cell redirecting bispecific antibodies for treatment of disease | |
| AU2010286642B2 (en) | Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof | |
| JP2016520548A5 (cg-RX-API-DMAC10.html) | ||
| JP2014514345A5 (cg-RX-API-DMAC10.html) | ||
| US20110020273A1 (en) | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof | |
| US9931413B2 (en) | Tetrameric cytokines with improved biological activity | |
| CN105566498A (zh) | 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途 |